Micro Interventional Devices today said it received FDA breakthrough device designation for its MIA-T percutaneous tricuspid annuloplasty system. The MIA-T system treats moderate to severe tricuspid regurgitation through a 12F catheter-based system. Get the full story on our sister site, Medical Tubing + Extrusion.
Micro Interventional Devices
Catheter OEM Oscor gets in on $20m Series D for Micro Interventional Devices
Micro Interventional Devices said today that contract manufacturer Oscor led its $20 million Series D round and inked an OEM deal. Newtown, Pa.-based MID said the deal involves a non-exclusive license for Palm Harbor, Fla.-based Oscor’s catheter technology, in return for Oscor’s exclusive right to its MID’s Mia device for treating tricuspid and mitral valve […]
Neovasc inks $3m settlement deal with MID, raises $1m
Neovasc (NSDQ:NVCN) said today that it inked a $3 million settlement agreement with Micro Interventional Devices to resolve undisclosed allegations related to Neovasc’s transcatheter mitral valve replacement technology, including its flagship Tiara device, and added that it has raised approximately $1.2 million. The agreement includes payments totally approximately $3 million to be made by Neovasc to […]
Micro Interventional Devices touts early results in tricuspid repair trial
Micro Interventional Devices last week touted early results from a study of its minimally invasive annuloplasty technology as a treatment for severe tricuspid regurgitation. The technology has been successfully implanted percutaneously in four patients, the company reported. Get the full story at our sister site, Medical Design & Outsourcing.
Micro Interventional Devices begins study of tech for heart valve repair
The first patient in the transcatheter arm of a European study has been treated with Micro Interventional Devices’ MIA technology for tricuspid and mitral repair, the company said. A team at Vilnius University Hospital Santariskiu Clinic (Vilnius, Lithuania) used the 12F MIA (minimally invasive annuloplasty) delivery catheter and PolyCor anchors to reduce tricuspid annular dimensions and […]
Micro Interventional Devices touts 2nd valve repair with Mia device trial
Micro Interventional Devices said today it completed the 2nd successful procedure with its Mia device designed for percutaneous mitral and tricuspid repairs. The Newtown, Penn.-based company’s MIA implant is composed of PolyCor anchors and MyoLast implantable elastomer, and is designed to reduce annular dimensions and regurgitation after being deployed in the patient’s native annulus. “On Friday, February 3rd, […]
Micro Interventional Devices launches MIS annuloplasty trial
Micro Interventional Devices said yesterday it completed the 1st clinical implantation of its MIA implant in the STTAR clinical trial of the device, which is designed for minimally invasive mitral and tricuspid repair procedures. The Newtown, Penn.-based company’s MIA implant is composed of PolyCor anchors and MyoLast implantable elastomer, and is designed to reduce annular dimensions and […]
Micro Interventional Devices wins FDA nod for Permaseal
Micro Interventional Devices said today it won FDA 510(k) clearance for its Permaseal transapical access and closure device. The Permaseal device is designed to allow surgeons to access and close the left-ventricle without having to suture the myocardium using the companies compliant soft-tissue PolyCor anchor technology. “The FDA market clearance of Permaseal is another tremendous […]
Micro Interventional wins CE Mark for Permaseal transapical closure device
Micro Interventional Devices said today it won CE Mark approval in the European Union for its Permaseal transapical closure device. The Permaseal closure device is designed to allow surgeons to access and close the left-ventricle instantaneously without suturing the myocardium, the Newtown, Penn.-based company said. “The CE Mark approval of Permaseal is a tremendous achievement […]
Stung by widening losses, Accuray plans $75M debt offering | Wall Street Beat
Accuray (NSDQ:ARAY) plans to issue $75 million worth of convertible senior notes as it gears up to restructure its business after a year of widening losses.
The Sunnyvale, Calif.-based medical device company said it will use the proceeds from the offering of debt due Feb. 1, 2018, to shore up its balance sheet.
